Kevin Hung

Kevin Hung

Auto-generated profile, based on publicly available information

Kevin Hung

Royal Adelaide Hospital and SA Pathology, Central Adelaide Local Health Network Adelaide South Australia Australia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2025 in Blood Advances
Verified
Journal Article
Open access
MSMithun Vinod Shah
Mithun Vinod Shah
KHKevin Hung
Kevin Hung
ABAnmol Baranwal
Anmol Baranwal
MKMonika M. Kutyna
Monika M. Kutyna
AAAref Al-Kali
Aref Al-Kali
DHDevendra Hiwase
Devendra Hiwase
This retrospective analysis aimed to provide evidence-based risk stratification of TP53-mutated (TP53mut) myeloid neoplasms (MNs). Of 580 MNs harboring TP53mut with variant allele frequency (VAF) ≥2%, 219 (37.8%), 194 (33.4%), 92 (15.9%), and 75 (12.9%) were classified as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) with low blasts (MDS-LB), MDS with excess blasts (MDS-EB)-2, and -EB1 according to the revised fourth edition of the World Health Organization (WHO) classification, respectively. Hierarchical analysis identified the following 4 risk groups with distinct survival: (1) MDS-LB, (2) MDS-EB1/EB2/AML VAF <10%, (3) MDS-EB1/EB2 VAF ≥10%, and (4) AML VAF ≥10%. We next evaluated the impact of allelic status, VAF, and complex karyotype (CK). In our cohort, the significance of biallelic status was limited to MDS with <5% blasts and not for blasts 5% to 9%, as proposed by the International Consensus Classification (ICC), or 5% to 19%, as proposed by the fifth edition of the WHO (WHO-5). MDS-EB1 and -EB2 with VAF ≥10% had comparable survival (9.6 vs 7.2 months; P = .12), regardless of allelic status. Contrary to the ICC proposal, MDS-EB1/EB2 with VAF <10% and CK had poor survival compared with those without CK, comparable to MDS-EB1/EB2 with VAF ≥10% (5.6 vs 26.2 vs 6.3 months; P = .003). Survival of TP53mut AML was poor (median 3.9 months) regardless of allelic/CK status. Thus, using ICC or WHO-5 may underestimate prognosis of MDS with blasts 5% to 19% and 5% to 9%, respectively. Collectively, the hierarchical model acknowledges poor survival of 91.9% TP53mut MDS and AML compared with 36.5% and 80.7% by WHO-5 and ICC, respectively.

7 May 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
MSMithun Vinod Shah
Mithun Vinod Shah
KHKevin Hung
Kevin Hung
ABAnmol Baranwal
Anmol Baranwal
GWGauri Wechalekar
Gauri Wechalekar
AAAref Al-Kali
Aref Al-Kali
DHDevendra Hiwase
Devendra Hiwase
The World Health Organization (WHO-5) and International Consensus Classification (ICC) acknowledge the poor prognosis of TP53-mutated (TP53 mut) myeloid neoplasm (MN). However, there are substantial differences between the two classifications that may lead to under- or overestimation of the prognostic risk. We retrospectively applied WHO-5 and ICC to 603 MN cases harboring TP53 mut (variant allele frequency, VAF ≥ 2%). WHO-5 and ICC would not classify 64% and 20% of these cases as TP53 mut MN, respectively. Moreover, of those classified, 67.5% would be classified discrepantly. Primary drivers of discrepancies included: (i) prognostic importance of TP53 mut acute myeloid leukemia (AML), (ii) interaction of the blast percentage and allelic status, (iii) 17p.13.1 deletion detected by cytogenetics, (iv) complex karyotype (CK) as multi-hit equivalent, and (v) TP53 mut VAF threshold, we analyzed survival outcomes of each of these groups with an aim to provide clarity. TP53 mut AML was associated with significantly poor survival compared to TP53-wild type TP53 wt AML, myelodysplasia-related (AML, MR 4.7 vs. 18.3 months; P < 0.0001), supporting its inclusion within TP53 mut MN as a distinct subentity. Secondly, the survival of TP53 mut with blast 10–19% was poor regardless of the allelic status. Thirdly, for cases with a single TP53 mut with VAF < 50%, 17p13.1 del or CK serve as practical surrogates of biallelic inactivation, obviating the need for an additional copy number analysis. Finally, TP53 mut AML, MDS multi-hit/multi-hit equivalent with VAF < 10% had significantly poorer survival compared to TP53 mut MDS VAF < 10% without CK and 17p del, and were comparable to those with VAF ≥ 10% (14.1 vs. 48.8 vs.7.8 months, P < 0.0001). Collectively, these findings address key areas of contention and provide valuable insights that will guide future revisions of the WHO and ICC classifications.

27 June 2024 in Blood Advances
Verified
Journal Article
Open access
PVParvathy Venugopal
Parvathy Venugopal
PAPeer Arts
Peer Arts
LFLucy Fox
Lucy Fox
ASAnnet Simons
Annet Simons
DHDevendra K. Hiwase
Devendra K. Hiwase
HSHamish S Scott
Hamish S Scott

16 September 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
MPMikko Purhonen
Mikko Purhonen
MTMikael Tatun
Mikael Tatun
KLKatariina Luukkainen
Katariina Luukkainen
KHKevin Hung
Kevin Hung
HSHenri Sundquist
Henri Sundquist
OBOscar Brück
Oscar Brück
Treatment-free remission (TFR) has become a therapeutic objective for selected chronic-phase chronic myeloid leukemia (CP CML). However, no standardized biomarker is yet in clinical use. In this multi-center study, we explored the potential of bone marrow (BM) cytomorphology given its global accessibility and integral role in clinical diagnostics. We included diagnostic BM aspirate samples of 113 CP CML patients from seven clinical sites having attempted first TKI discontinuation. We digitized cytomorphological slides into 100x-magnified high-resolution images and analyzed these with deep learning-based image analysis. We profiled the BM cytomorphological fingerprint of CP CML patients and recapitulated the known granulocytic predominance and reduction of lymphoid, monocytic and erythroid cells in comparison to an extensive cohort of 942 control BM samples. We discovered neutrophil abundance and granulocytic maturation to associate with sustained TFR. We confirmed these visually and demonstrated their independent impact over known clinical factors. Our study underlines the potential of computational BM cytomorphology to identify novel clinical biomarkers and suggests that granulocytic expansion and maturation at diagnosis could reflect intrinsic disease pathology influencing TFR maintenance.

19 July 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
MWMihir D. Wechalekar
Mihir D. Wechalekar
LZLin-Pierre Zhao
Lin-Pierre Zhao
MKMonika M. Kutyna
Monika M. Kutyna
LHLih En Hong
Lih En Hong
JLJoule Li
Joule Li
DHDevendra Hiwase
Devendra Hiwase
Myeloid neoplasms arising after methotrexate

15 August 2025 in Blood Advances
Verified
Journal Article
Open access
TWThomas Wiseman
Thomas Wiseman
MSMichaela Spooner
Michaela Spooner
SKShreyas Khanna
Shreyas Khanna
KHKevin Hung
Kevin Hung
CTCarla R. Toop
Carla R. Toop
DHDevendra Hiwase
Devendra Hiwase